All In Biotech

Drug Trial Radar · NCT06922357

A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors

A Phase I/II, Open-label, Multi-centre Study Evaluating the Safety,Tolerability,Pharmacokinetic (PK), Pharmacodynamics, and Preliminary Efficacy of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors With MTAP Deficiency

Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Apr 24, 2025

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Apr 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I/II, multicenter, open-label clinical trial with dose escalation/dose expansion/efficacy expansion phases, designed to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic (PK/PD) profiles, and antitumor efficacy characteristics of HRS-6719 in patients with MTAP-deficient advanced solid tumors.

Conditions

  • Advanced/Metastatic Solid Tumors

Interventions

  • HRS-6719Drug

    HRS-6719

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limited Toxicity (DLT)Time frame: 21 Days (first cycle)
  2. Maximum tolerable dose (MTD)Time frame: 21 Days (first cycle)
  3. Recommended dose for phase II (RP2D)Time frame: through phase I completion, an average of 1 years
  4. Incidence and severity of AETime frame: from Day1 to 30 days after last dose

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Barbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.